Top Markets
Coin of the day
Crossject Société Anonyme Crossject Société Anonyme

Crossject Société Anonyme

ALCJ
株式のランク #12697
Crossject Société Anonyme develops needle-free injection systems. The company... Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
株価
$2.04
時価総額
$122.58M
変化(1日)
4.48%
変化(1年)
-1.05%
FR
取引 Crossject Société Anonyme (ALCJ)

カテゴリー

Crossject Société Anonyme(ALCJ)の利益
Dec 2025 時点の利益 TTM: $-15.47M
Crossject Société Anonyme の最新の財務報告によると、同社の現在の利益は $-15.47M です。2023 年には $-12.72M の利益を上げ、これは 2022 年の利益 $-14.35M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Crossject Société Anonyme の利益の推移(2010 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-15.47M -4.84%
2024 $-16.25M 27.80%
2023 $-12.72M -11.38%
2022 $-14.35M -0.03%
2021 $-14.36M 2.59%
2020 $-13.99M 46.56%
2019 $-9.55M -32.47%
2018 $-14.14M 34.82%
2017 $-10.49M 28.48%
2016 $-8.16M 11.67%
2015 $-7.31M 13.90%
2014 $-6.42M 95.21%
2013 $-3.29M 78.49%
2012 $-1.84M -292.97%
2011 $954.59K -114.97%
2010 $-6.38M 0.00%
同業他社の利益
企業 利益 利益の差
$3.58B -23,265.34%
US
$3.75B -24,333.92%
FR
$414.52M -2,779.78%
DE
$2.17B -14,118.05%
JP
$1.74B -11,342.30%
US